These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18604455)

  • 1. Towards immunotherapeutic drugs and vaccines against multiple sclerosis.
    Katsara M; Matsoukas J; Deraos G; Apostolopoulos V
    Acta Biochim Biophys Sin (Shanghai); 2008 Jul; 40(7):636-42. PubMed ID: 18604455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
    Ulzheimer JC; Meuth SG; Bittner S; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Aug; 24(4):249-74. PubMed ID: 20623991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel promising therapeutic agents in multiple sclerosis.
    Mirshafiey A
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):218-4. PubMed ID: 19075984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of disease-modifying drugs on the severity of  COVID-19 infection in multiple sclerosis patients.
    Rostami Mansoor S; Ghasemi-Kasman M
    J Med Virol; 2021 Mar; 93(3):1314-1319. PubMed ID: 33044760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F; Kieseier BC
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current state of research on multiple sclerosis].
    Lubina-Dabrowska N; Stepień A; Chalimoniuk M
    Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S; Hohlfeld R; Voltz R
    MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy in multiple sclerosis.
    Milo R; Panitch H
    J Neuroimmunol; 2011 Feb; 231(1-2):23-31. PubMed ID: 21111490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].
    Kleinschnitz C; Meuth SG; Kieseier BC; Wiendl H
    Nervenarzt; 2007 Aug; 78(8):883-911. PubMed ID: 17551708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: Therapeutic applications of advancing drug delivery systems.
    Dolati S; Babaloo Z; Jadidi-Niaragh F; Ayromlou H; Sadreddini S; Yousefi M
    Biomed Pharmacother; 2017 Feb; 86():343-353. PubMed ID: 28011382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical guide to pediatric multiple sclerosis.
    Huppke P; Gärtner J
    Neuropediatrics; 2010 Aug; 41(4):157-62. PubMed ID: 21086219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.
    Vidal-Jordana A; Montalban X
    Neuroimaging Clin N Am; 2017 May; 27(2):195-204. PubMed ID: 28391781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A changing treatment landscape for multiple sclerosis: challenges and opportunities.
    Piehl F
    J Intern Med; 2014 Apr; 275(4):364-81. PubMed ID: 24444084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choosing drug therapy for multiple sclerosis. An update.
    van Oosten BW; Truyen L; Barkhof F; Polman CH
    Drugs; 1998 Oct; 56(4):555-69. PubMed ID: 9806103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavonoids, the compounds with anti-inflammatory and immunomodulatory properties, as promising tools in multiple sclerosis (MS) therapy: A systematic review of preclinical evidence.
    Bayat P; Farshchi M; Yousefian M; Mahmoudi M; Yazdian-Robati R
    Int Immunopharmacol; 2021 Jun; 95():107562. PubMed ID: 33770729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis treatment: current best practice.
    Niino M
    Expert Rev Clin Immunol; 2012 Aug; 8(6):505-7. PubMed ID: 22992142
    [No Abstract]   [Full Text] [Related]  

  • 20. Switching therapies in MS: what are the options?
    Markowitz CE
    J Clin Psychiatry; 2015 Feb; 76(2):e6. PubMed ID: 25742221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.